Greenfern Industries Limited has announced reaching an agreement with Australian based Cannvalate Pty Ltd, to develop cannabis medications sales in Australia.
The agreement includes the issuance of shares in Greenfern to Cannvalate of a value of NZD $900,000, along with access to deidentified patient data to inform R&D initiatives and educational resources for physicians.
The agreement is expected to increase GFI Pharma's product lines, and further accelerate the development of Greenfern in the industry.
See more
